Market Signal Briefing

Key takeaways:

ETH derivatives exhibit a fading bullish appetite as Ethereum’s TVL declines and network fees decrease, reinforcing persistent risk aversion.

US job layoffs climb, and seasonal hiring weakens, leaving traders waiting for fresh liquidity before rebuilding confidence in ETH’s near-term upside.

Ether (ETH) has climbed 15% from its $2,623 low made last Friday, yet derivatives metrics show traders remain cautious. The absence of bullish leverage from top ETH traders, combined with falling Ethereum network fees, weakens the case for sustained upside. As a result, traders question what must shift for ETH to convincingly reclaim the $4,000 mark.

ETH perpetual futures annualized funding rate. Source: laevitas.chDemand for leveraged bullish ETH positions has been virtually absent since Monday, as indicated by the perpetual futures funding rate. Under normal conditions, this rate should sit between 6% and 12% to offset capital costs. Still, a meaningful portion of the current hesitation stems from uncertainty following the October flash crash.

The 20% Ether price plunge on Oct. 10 sparked widespread liquidations across centralized and decentralized venues, dealing a major blow to trader confidence. total value locked (TVL) on the Ethereum network slid to $72.3 billion from $99.8 billion on Oct. 9, according to DefiLlama data. This contraction in deposits adds pressure to ETH’s price outlook, as investors brace for softer demand.

Blockchains ranked by 7-day network fees, USD. Source: NansenEthereum network fees dropped 13% over the past week, even though transaction counts held steady. That divergence has investors worried about a negative feedback loop tied to shrinking network deposits, which could ultimately produce an inflationary tilt for ETH. After all, Ethereum’s burn mechanism relies entirely on sustained onchain activity.

ETH top traders' long-to-short ratio at OKX. Source: CoinGlassWhen aggregating spot, futures and margin positions, top traders at OKX have trimmed their bullish exposure to ETH. The long-to-short ratio now shows a 23% tilt toward bearish positions. More importantly, whales and market makers have repeatedly failed to maintain meaningful bullish leverage, signaling a clear lack of conviction.

Ether traders await clarity as weak US labor data erodes confidenceAnother driver of traders’ unease is the weakening US job market. Some companies have cited rising operating costs, while consumer spending dropped following the US government shutdown that lasted until Nov. 12, according to Yahoo Finance. Reuters reported that US-based firms have announced more than 25,000 job cuts in November. 

Adam Sarhan, chief executive of 50 Park Investments in New York, reportedly said: “You don't have mass layoffs when the economy is strong.” If layoffs accelerate, they could further dent consumer confidence and weigh on risk assets, including Ether. 

US federal government surplus or deficit, USD. Source: Federal ReserveThe US government must keep expanding debt to sustain growth because slowing revenues and rising costs outpace economic momentum, while large-scale artificial intelligence infrastructure spending takes years to deliver productivity gains or meaningful returns to the broader economy. Large deficits favor alternative investments, which could be a potential trigger for Ether’s price.

While the soft labor backdrop hurts market sentiment, a weaker economy could also nudge the US Federal Reserve toward a more accommodative stance. Moreover, the risk-off environment eased after the reversion of the slowdown in economic activity triggered by the United States government shutdown that lasted until Nov. 12. 

Historically, cryptocurrencies have benefited from such conditions; however, the current lack of clarity in the US employment picture continues to erode trader confidence. It remains unclear whether Ether can reclaim $4,000 before fresh liquidity injections from major central banks arrive to support global growth. 

For now, investors appear more focused on tech equities and bond markets, leaving limited room for a short-term upside move in ETH.

This article is for general information purposes and is not intended to be and should not be taken as legal or investment advice. The views, thoughts, and opinions expressed here are the author’s alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

Ripple's USD stablecoin just unlocked a powerful regulatory gateway in Abu Dhabi, clearing a path for accelerated institutional adoption across the Middle East and positioning RLUSD as a breakout force in global digital finance. Ripple USD Gains Major Middle East Regulatory Momentum Ripple announced on Nov.

As the market matures and the broader economic landscape shifts, Bitcoin has once again found itself at a thrilling crossroads, with the entire crypto market watching closely as momentum builds on both sides of the chart. This moment of market volatility is a profound inflection point, where the interplay of rising institutional adoption and changing global macroeconomic conditions is converging.

Historical Breakout Zones Align With Price Structure
Bitcoin is currently sitting at a thrilling crossroads. In an X post, an analyst known as CryptoCrewU has stated that BTC is witnessing the strongest bearish divergence in years, paired with a rare 2-week close below the 21-period Simple Moving Average (SMA) of this bull run.

Furthermore, the Relative Strength Index (RSI) is currently dipping into levels reminiscent of past pivotal moments in 2015, 2018, the COVID-19 pandemic, and the 2022 bottoms. Meanwhile, the Stoch RSI has yet to cross upwards, hinting at the full extent of the potential move ahead.

While fear is at its peak in the market right now, history shows that buying during these market lows has consistently led to significant profits over the past 5 years. “Let data guide you, not emotions,” CryptoCrewU noted.

Trader_XO highlighted that since 2015, one pattern has remained remarkably consistent in Bitcoin’s cycle. Historically, whenever breaks below the 50-week Moving Average (MA), it has often signaled a deeper move toward the 200-week MA, or even the 300-week MA. Meanwhile, BTC tends to treat the 200-week MA as a major cycle support area. 

The price has only dipped below the 300-week MA once in history, and anything trading below the 200-week MA has been relatively short-lived, aligning with the best part of the cycle lows. According to Trader_XO, if the price were to revisit those lower moving average levels, and the broader market context aligns, that area would be viewed as a high-probability buying opportunity, unless this time the move is different.

Market Structure Shows Early Signs Of Strength Returning
Bitcoin is finally showing signs of strength again. A Full-time crypto teacher, Sykodelic, has pointed out that for the first time since the drop from $116,000, the price has broken above its previous low-time-frame (LTF) range, with a strong push above the 50 SMA. 

Since the $116,000 rejection, every time BTC attempts to move into an upper range, it gets rejected and makes new lows. This time, BTC has finally pushed higher. Currently, this is simply an LTF action, but these subtle shifts are exactly what to watch out for when it comes to understanding the nature of trend reversals.

A daily close above $87,000 will confirm the breakout of the trend. Sykodelic concluded that moving higher after a drop like that is intricate, and it can take time. Therefore, observe the signs and move accordingly to see how the daily close goes.

BTC trading at $91,478 on the 1D chart | Source: BTCUSDT on Tradingview.com
Featured image from Pngtree, chart from Tradingview.com

Justin Sun, in a media briefing he held in Hong Kong titled “Truth Unveiled, Justice Revealed,” has shared an update on the ongoing effort to recover $456 million in missing TUSD reserves.

Flowdesk and QCP see short covering and dip buying supporting BTC around $90,000, while prediction markets assign low odds of a push toward $96,000.

Tuesday's pre-deposit event faced outages, changes in deposit cap, and a misconfigured multisig transaction.

XRP has failed to recover its H2 2025 losses, as whales continue to take profits on key market events, capping the upside.

XRP-Spot ETF Inflows Signal Uncertain Demand Outlook
The US XRP-spot ETF market extended its inflow streak to nine sessions on Wednesday, November 26. The four ETF issuers reported net inflows of $21.81 million, following inflows of $35.41 million the previous day. There was no spot ETF trading on Thursday, November 27, because of the Thanksgiving holiday.

Notably, the XRP-spot ETF market has seen total net inflows of $643.92 million since the launch of the Canary XRP ETF (XRPC) on November 14.

With a first-to-market advantage, XRPC leads the way, with net inflows of $334.59 million, the lion’s share of which came on day one of trading ($243.05 million).

By contrast, Franklin XRP ETF (XRPZ) has seen net inflows of $74.54 million since its November 24 launch. Analysts expected XRPZ to lead the way, given Franklin Templeton’s #19 ranking on the ETF Issuer AUM League Table. Franklin Templeton has an ETF AUM of $43.94 billion, while Canary has an ETF AUM of just $349 million and ranks at #153.

Crucially, waning inflows into XRP-spot ETFs could temper expectations for the launch of a BlackRock (BLK) iShares XRP Trust. The absence of the ETF juggernaut in the spot XRP space may limit the market’s success. BlackRock has been pivotal to the success of the BTC-spot and ETH-spot ETF markets. Notably, an iShares XRP Trust would suggest a robust demand pipeline, a bullish price signal.

Since launch, iShares Bitcoin Trust (IBIT) has seen net inflows of $62.68 billion. Meanwhile, Fidelity Wise Origin Bitcoin Fund (FBTC), the second-largest BTC-spot ETF, has reported net inflows of just $11.96 billion.

Fed Rate Cut Bets Send Bitcoin Higher
While XRP-spot ETF flows left XRP on the back foot, rising bets on a December Fed rate cut drove demand for BTC and the broader market.

According to the CME FedWatch Tool, the probability of a December rate cut rose from 39.1% on November 20 to 86.9% on November 27, lifting demand for risk assets.

Bitcoin gained 0.93% on Thursday, November 27, consolidating its return to the $90,000 level after plunging to a November 21 low of $80,523. BTC’s price recovery can be attributed directly to revived bets on a Fed rate cut, which renewed demand for BTC-spot ETFs.

Spot ETF inflows remain a key price driver for XRP and BTC. However, US economic data, Fed speeches, and market sentiment toward a December Fed rate cut will also influence near-term price trends.

Technical Outlook: Key XRP Price Levels
XRP fell 1.03% on Thursday, November 27, reversing the previous day’s 0.97% gain to close at $2.2001. The token underperformed the broader market, which advanced 0.39%, and extended its losses early in the Friday, November 28 session, breaking below $2.2.

Thursday’s reversal left XRP well below the 50-day and 200-day Exponential Moving Averages (EMAs), indicating a bearish bias.

Looking ahead, several key events are likely to influence XRP’s price outlook.

Key technical levels to watch include:

Support levels: $2, $1.9112, and $1.8239
50-day EMA resistance: $2.3631.
200-day EMA resistance: $2.5182.
Resistance levels: $2.2, $2.35, $2.5, $2.62, $2.8, $3.0, and $3.66.

Journalist

Posted: November 28, 2025

Key Takeaways
What’s driving SKY price action up?
SKY price rose from the surge in buybacks, daily trading volume, staking activity, and market structure shifts.

Will SKY hold up to the uptrend?
If the price stays above the broken trendline, SKY could rally back to the $0.0620 level.

Sky [SKY] has potentially started its recovery, regaining the $1 billion market cap.

The ecosystem is racking up penalties, with more than 84% upgraded to SKY. This comes with a 10,000 MKR upgrade in the past month, accumulating about $100K in fees.

In the past 24 hours, SKY price rallied by more than 10%, driven by volume and the buyback program. The daily volume increased by 78%, indicating more trading activity, according to CoinMarketCap.

Why is SKY’s price up today? 
According to SKY Money, buybacks have been steadily rising since early November. At press time, the total buybacks stood at 1.395 billion tokens, valued at $65.64 million, following the addition of 6.21 million tokens.

However, currently, the buybacks have slowed, dropping by 2,250 SKY despite being only halfway complete. On average, each transaction has been worth about $10,000, based on SKY Money data.

Source: SKY Money

Furthermore, the altcoin was seeing a surge in staking, which meant increased network security. About 35.94%, equivalent to $385.48 million, of SKY was staked.

According to DefiLlama, daily volume rose by $10 million to $23.55 million, an increase of 1.7% from the previous day’s $13.44 million.

Source: DefiLlama

Additionally, the fees for the fourth quarter were $26.75 million. Nevertheless, this was less than the $45.3 million recorded in the previous quarter.

Will TVL hinder price appreciation?
SKY broke above a descending trendline on the 4-hour charts and confirmed with a retest. The trendline has been in play for the last two weeks, which indicates seller dominance during this period.

This seller action was once again evident on the charts after the price hit the $0.050 zone. Consequently, the RSI and Bull Bear Power (BBP) indicators started showing a shift in direction.

At the time of writing, the RSI rejected the oversold threshold, while the BBP decreased from 0.00625 to 0.00389. This was an indication of buyer exhaustion or profit-taking following this mini surge.

The double-digit rally elicited the sentiment that SKY could have hit its bottom. This is due to the slight recoveries seen in the altcoin market in the past few days. If the uptrend continues, the altcoin could potentially reach $0.0620 or beyond.

Source: TradingView

However, there was a risk of reversal after the Gravestone Doji, which is a signal for bear reversals or pullbacks during uptrends.

While there was anticipation for a further uptrend, the Total Value Locked in the ecosystem was dipping. In the past thirty days, TVL declined from $7.7 billion to $6.6 billion, which could challenge this trajectory.

Source: DappRadar

These metrics for SKY show mixed sentiments, though they leaned more on the bullish side. However, for this to be sustained, SKY’s price needed to hold above the broken trendline.

Ethereum price started a recovery wave and surged above $3,000. ETH might continue to rise if it clears the $3,080 resistance.

Ethereum started a recovery wave above $2,980 and $3,000.
The price is trading above $2,960 and the 100-hourly Simple Moving Average.
There is a key bullish trend line forming with support at $2,950 on the hourly chart of ETH/USD (data feed via Kraken).
The pair could continue to move up if it settles above the $3,080 zone.

Ethereum Price Eyes More Gains
Ethereum price managed to stay above $2,880 and started a recovery wave, like Bitcoin. ETH price was able to climb above the $2,920 and $2,950 levels.

The bulls were able to push the price above the 61.8% Fib retracement level of the downward move from the $3,165 swing high to the $2,620 low. The bulls even pumped the price above $3,000 but they struggled to clear the $3,080 zone.

The price failed to settle above the 76.4% Fib retracement level of the downward move from the $3,165 swing high to the $2,620 low. Ethereum price is now trading above $2,960 and the 100-hourly Simple Moving Average. Besides, there is a key bullish trend line forming with support at $2,950 on the hourly chart of ETH/USD.

Source: ETHUSD on TradingView.com
If there is another upward move, the price could face resistance near the $3,050 level. The next key resistance is near the $3,080 level. The first major resistance is near the $3,120 level. A clear move above the $3,120 resistance might send the price toward the $3,165 resistance. An upside break above the $3,165 region might call for more gains in the coming days. In the stated case, Ether could rise toward the $3,220 resistance zone or even $3,250 in the near term.

Another Decline In ETH?
If Ethereum fails to clear the $3,080 resistance, it could start a fresh decline. Initial support on the downside is near the $2,950 level. The first major support sits near the $2,880 zone.

A clear move below the $2,880 support might push the price toward the $2,840 support. Any more losses might send the price toward the $2,800 region in the near term. The next key support sits at $2,750 and $2,740.

Technical Indicators

Hourly MACD – The MACD for ETH/USD is losing momentum in the bullish zone.

Hourly RSI – The RSI for ETH/USD is now below the 50 zone.

Major Support Level – $2,950

Major Resistance Level – $3,080

A new proposal on Balancer’s governance forum sets the stage for how the protocol plans to handle the next phase of its recovery effort.

Summary

Balancer has proposed a framework to distribute $8M in rescued assets after the V2 exploit.
Whitehats would receive 10% bounties, while LP repayments would be pro-rata and paid in-kind.
The Nov. 3 attack drained over $128M, prompting coordinated recoveries and community-wide mitigation efforts.

Balancer has outlined a reimbursement plan that would return roughly $8 million in rescued assets to liquidity providers affected during the v2 exploit.

The Nov. 27 proposal is the protocol’s first concrete step toward settling losses after one of decentralized finance’s largest breaches this year.

How the repayment plan would work
The proposal details how funds recovered by whitehat responders and internal rescue teams will be distributed. According to Balancer (BAL), the $8 million was secured across several networks after the exploit, while an additional $19.7 million tied to osETH and osGNO is being processed separately by StakeWise.

Under the plan, whitehat actors who intervened during the attack would receive bounties equal to 10% of the assets they helped recover, paid in the same tokens they returned.

Balancer’s Safe Harbor Agreement requires full identity verification, KYC screening, and sanctions checks before payouts are made. The foundation has already cleared compliance for the whitehats involved, though identities will remain confidential.

The proposal also outlines how internally recovered funds, secured in coordination with Certora, will be treated. Because Certora acted under an ongoing service agreement, these recoveries fall outside the bounty program. Instead, the tokens will be returned directly to the affected pools.

Liquidity providers would receive repayments on a pro-rata basis, matched to their BPT holdings at snapshot blocks taken just before the first exploit transactions on each network. 

The distribution would be non-socialized, meaning each pool’s recovered assets go only to LPs in that same pool. Payments would also be made in-kind, giving users the same tokens that were rescued.

A claim interface will be built, and users will need to agree to Balancer’s terms before receiving funds. Any unclaimed assets after the claim window closes would be redirected through a later governance vote.

A look back at the November exploit
The attack on Nov. 3 drained more than $128 million across Ethereum and multiple layer-2 networks, exploiting a precision-loss flaw in Balancer’s v2 pool invariant. The attacker manipulated the token balances, creating a loop of profitable arbitrage that emptied the pools in just a few minutes.

While most stolen assets were quickly moved through mixers, coordinated whitehat responses and protocol-level interventions prevented deeper losses. StakeWise recovered about $19 million in osETH shortly after the incident, and Balancer paused affected pools to contain further damage.

The new reimbursement plan now moves to community review, setting up the next governance vote as Balancer works to close one of its most disruptive chapters of 2025.

The issues began immediately at launch, when transactions failed because the contract contained an incorrect SaleUUID, requiring a 4-of-6 multisig update.

Justin Sun has intensified his global campaign to recover the missing $456 million in TUSD reserves, following a major legal breakthrough secured through the Dubai International Financial Centre (DIFC) Court. In a Hong Kong media briefing titled “Truth Unveiled, Justice Revealed,” Sun announced that the case has now entered a more aggressive enforcement phase.

The DIFC Court issued an indefinite worldwide asset freeze on Aria Commodities DMCC and related entities on October 17. This marks the first global freeze in the ongoing dispute and blocks any movement of funds connected to the alleged fraud. The ruling applies across multiple jurisdictions, strengthening Sun’s efforts to trace and recover the missing reserves.

Sun expressed strong confidence in the ruling, calling it “fair and resolute,” adding that his team is tracing reserve assets across international markets. “Justice may be delayed, but it will never be denied,” he said, reinforcing that “full recovery and restitution” remain the top priority.

Investigations Expand Across Hong Kong, Dubai, Cayman Islands
With the freeze order now active, the case is entering a new phase of legal action. Authorities across Hong Kong, Dubai, the Cayman Islands, and other regions are expected to escalate investigations. Sun stated that additional evidence and recovery steps are already underway, with ongoing probes targeting individuals, including Vincent Chok, Matthew Brittain, and former TrueCoin executives.

How the $456 Million Went Missing
The dispute dates back to 2020 after Techteryx acquired TUSD. TrueCoin, the token’s original operator, continued managing reserves. However, investigations show that TrueCoin, First Digital Trust (FDT), Legacy Trust, and offshore entities tied to Matthew Brittain allegedly fabricated documents, submitted misleading filings, and moved funds out of regulated custody.

The diverted reserves were reportedly transferred to bank accounts connected to Aria DMCC, a Dubai firm owned by Brittain’s spouse. Evidence suggests that FDT CEO Vincent Chok approved and facilitated these transfers, allegedly receiving kickbacks. The U.S. SEC later accused TrueCoin of misleading investors about TUSD’s reserves, exposing deeper operational misconduct.

Sun’s Role in Preventing TUSD Collapse
Despite the controversy, TUSD has maintained near-dollar stability largely due to Justin Sun’s support. As previously reported by Cryptopolitan, Sun issued a significant loan of around $450 million to stabilize Techteryx and prevent disruption for holders.

FDT has denied Sun’s accusations, with Chok stating there is no evidence to support the claims and signaling intent to pursue legal action. Sun, however, remains firm and prepared for a multi-jurisdictional legal fight, framing his efforts as protection for the broader crypto ecosystem.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Cryptocurrency investments are volatile and risky. Always conduct your research before making any investment decisions

BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of patients with prurigo nodularis in China.

Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The Current indications under development are strategically positioned within the vast dermatology market, including atopic dermatitis, vitiligo, prurigo nodularis, urticaria, and more. TYK2 plays a key role in the JAK-STAT signaling pathway and is critical in the pathogenesis of inflammatory diseases.

Prurigo nodularis is a chronic inflammatory skin disease characterized by severe itching and skin nodules, which significantly impairs patients’ quality of life. Soficitinib alleviates symptoms by blocking the signaling pathways of cytokines related to itching and inflammation, such as IL-4, IL-13, and IL-31, thereby reducing neurogenic itch responses and inhibiting skin inflammation.

There are about 10 million patients with prurigo nodularis worldwide1. The global prurigo nodularis market was valued at US$2 billion in 2024 and is expected to grow to US$3 billion in 20342.

Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, said, “InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions. The Phase II clinical study of Soficitinib for moderate-to-severe atopic dermatitis demonstrated outstanding efficacy and a strong safety profile. The data has been released as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting. We are accelerating global clinical development to bring innovative therapies to more autoimmune patients as early as possible.”

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.

InnoCare Forward-looking Statements

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

___________________________
1 https://doi.org/10.1111/jdv.20585
2 Global Market Insights

Marks the solid execution of FF and FX’s Global Automotive Bridge Strategy in the Middle East, signaling a new phase in the Company’s Middle East Three-Pole strategy and lays a core foundation for future sales.FF and FX will expand Co-Creation initiatives with FX Super One’s first global owner and Developer Co-Creation Officer Andrés Iniesta, accelerating the Middle East’s transition into the new era of EAI-MPV mobility.
FX Super One will begin broader deliveries in the UAE, with the goal of becoming the region’s leading MPV. DUBAI, United Arab Emirates, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (Nasdaq: FFAI) (“Faraday Future,” “FF,” or “the Company”), a global shared intelligent electric mobility ecosystem company headquartered in California, announced today that the Company hosted a Co-Creation Delivery Ceremony in the UAE for FX Super One’s first global owner and Developer Co-Creation Officer, soccer legend Andrés Iniesta. FF Global Co-CEO Matthias Aydt, Head of FF Middle East Tin Mok, and Head of UES and Government Affairs for FF Middle East Morris Gao were among those who attended the event.

“I am honored to be the first global owner and Co-Creation Officer of FX Super One. This represents not only owning a First Class EAI-MPV but also taking an early step into the new era of AI mobility. I look forward to seeing FX Super One become a defining model in the Middle East MPV segment and a co-creator of AI-driven green mobility,” Andres Iniesta stated.

Tin Mok stated: “The delivery to Iniesta holds special significance. It marks the beginning of FX Super One deliveries in the UAE and lays a solid foundation for our upcoming sales efforts, while the Company continues preparation in parallel for the first U.S. pre-production vehicle to roll-off the line by year-end.”

FF and FX will continue expanding co-creation initiatives with Mr. Iniesta, working together to accelerate the Middle East’s transition into the new era of EAI MPV mobility. The FX Super One was officially launched in Dubai on October 28. It is planned to be available in two powertrain options: initially the AIHER, and later the battery electric (AIEV), with each offering four editions: GOAT, Max, Pro, and Standard. The first model introduced in the Middle East, the FX Super One AIHER Max, is priced at AED 309,000 (approximately USD $84,000). Within 48 hours of its launch, the Company received three non-binding non-refundable paid preorders covering over 200 units.

“Launching FX Super One deliveries in the Middle East is a key milestone in FF and FX’s global strategy,” said Matthias Aydt. “It marks our official transition in the UAE from the operational phase into the revenue phase, signifies the initial alignment of FF and FX’s Global Automotive Bridge Strategy in the Middle East, and signals a new phase in our Middle East Three-Pole strategy.”

ABOUT FARADAY FUTURE  

Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company’s mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future’s flagship model, the FF91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. For more information, please visit https://www.ff.com/us/.

FORWARD LOOKING STATEMENTS  

This press release includes “forward looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding future FX production, delivery and sales, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important factors, among others, that may affect actual results or outcomes include, among others: the Company’s ability to secure agreements with OEMs to sell FX vehicles in the UAE and elsewhere; the ability of OEMs and suppliers to timely delivery products and parts to the UAE; the Company's ability to homologate FX vehicles for sale in the Middle East, the U.S. and elsewhere; the Company’s ability to secure the necessary funding to execute on the FX strategy, which will be substantial; and the Company’s ability to continue as a going concern and improve its liquidity and financial position. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-K filed with the SEC on March 31, 2025, and Form 10-Q filed on August 19, 2025, and other documents filed by the Company from time to time with the SEC.

CONTACTS:  

Investors Relations (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f04aa3a-bc0b-44ae-8ee0-f41b205bd285

November 27, 2025 9:30 PM EST | Source: Trimera Metals Corp.
Vancouver, British Columbia--(Newsfile Corp. - November 27, 2025) - Trimera Metals Corp. (CSE: TRM) (OTCQB: TRMMF) (FSE: O2S) ("Trimera" or the "Company") is pleased to announce that it has changed its name from "Trimera Metals Corp." to "United Critical Minerals Corp." and its Canadian Securities Exchange ("CSE") ticker symbol from "TRM" to "UCM" (together, the "Name and Symbol Change").

The Company's common shares (the "Common Shares") will commence trading under its new name and with a new CUSIP and ISIN number on the CSE at market open on December 1, 2025. For further details, please see the CSE's bulletin dated November 27, 2025.

In connection with the Name and Symbol Change, the following new CUSIP (91016A108) and ISIN (CA91016A1084) numbers have been assigned to the Common Shares. No action is required to be taken by shareholders with respect to the Name and Symbol Change. Outstanding Common Share and warrant certificates bearing the former name of the Company are still valid and will not be affected by the Name and Symbol Change.

The Company's CEO and Director, Patrick Donnelly, states, "due to the high demand for critical metals in the United States, we intend to focus on securing top-tier projects to support the new geopolitical strategy in the west. We have already devoted substantial resources to exploring critical metals projects, including our Tahlo Lake project, and believe that our name change to "United Critical Minerals Corp." better reflects our strategic shift and encapsulates our focus on critical metals."

On Behalf of the Board of Directors

Patrick Donnelly
CEO & Director

About United Critical Minerals Corp.

United Critical Minerals Corp. is a junior exploration company focused on the exploration, development, and advancement of its Tahlo Lake property, located in south-central British Columbia. Tahlo Lake is comprised of four wholly owned mining claims totaling approximately 1,692 hectares.

For more information, please consult the Company's filings, available at www.sedarplus.ca.

Cautionary Note on Forward-Looking Information
The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements and includes statements respecting: the effective date of the Name and Symbol Change; the Company's intention to focus on securing top-tier projects to support the new geopolitical strategy in the west; and the Company's strategic shift and focus on critical metals. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release.

NOT FOR DISTRIBUTION TO THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276245

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

VANCOUVER, British Columbia, Nov. 27, 2025 (GLOBE NEWSWIRE) -- South Star Battery Metals Corp. (“South Star” or the “Company”) (TSXV: STS) (OTCQB: STSBF) is pleased to report its operating and financial results for the quarter ended September 30, 2025 and an additional update on operations.

South Star’s Interim Chief Executive Officer, Tiago Cunha, commented,

“We are pleased to announce that we have turned a significant corner with the operational issues at the plant. With the successful oversubscribed raise of US$4.8 million, we are now funded to continue the plant upgrades at the Santa Cruz Graphite Mine and on track to restart production in 2026, marking a new chapter of growth and resilience for the Company.”

Corporate Highlights During the Quarter

Appointments of Tiago Cunha as Interim CEO, Darren Prins as CFO and Corporate Secretary, and Rogerio Barcellos as General Manager.Successful completion of initial financing over the July/August 2025 of private placement for gross proceeds of US$302,610 (C$415,263).Announced (and subsequently closed on November 21, 2025) an over-subscribed private placement for gross proceeds of US$4,800,000 (C$6,672,000), with cash levels sufficient to sustain operations throughout 2026.Announced non-binding indicative term sheet for a US$4,000,000 loan facility with Sprott Streaming over a 3-year maturity period for the Santa Cruz Graphite Mine in Brazil, which is expected to provide additional resources for the execution of the Company’s strategic plan. Operations Update

Two critical pieces of equipment required for the plant restart have been purchased, with delivery timelines improved. The scrubber’s lead time was reduced from 180 days to 90 days at no additional cost, while the dryer remains on schedule. Additional initiatives originally budgeted for in the restructuring plan were completed at no cost through workforce mobilization under new management, demonstrating the Company’s cultural transformation and its impact on productivity and costs.

We completed a comprehensive review of our cost structure, achieving significant savings through contract renegotiations, process optimization, and elimination of inefficiencies. While some savings will take time to materialize due to contract terms, the Company expects to realize the full impact over the coming months, with estimated reductions of approximately 60–65% compared to historical costs.

The Company has strengthened its team with technical professionals aligned to production and plant operations and fostered a culture focused on quality, results, and relentless pursuit of improvement. South Star employees represented the Company at ExpoIbram 2026—the first time the Itabela operation participated in this event.

Installation and commissioning of the new equipment are expected to be completed during 2026, enabling stable production free from climate-related disruptions experienced in 2025. The Company expects to reach annualized output of 5,000 tonnes by mid-2026, after which the Company plans to install a new filter press to expand capacity to 10,000 tonnes per year by year-end 2026. With this installed capacity, the Company anticipates operating above breakeven levels, generating positive free cash flow, and strengthening its financial position.

Selected Financial Data

The following selected financial data is summarized from the Company’s financial statements and related notes thereto for the three and nine months ended September 30, 2025 and 2024.

 Three months ended
September 30,
  Nine months ended
September 30,
   2025  2024  2025  2024   $  $  $  $  Loss and comprehensive loss(823,278) (1,289,812) (30,523) (6,104,622) Loss per share – basic and diluted(0.02) (0.03) (0.03) (0.09)    September 30,
2025 December 31,
2024  $ $ Cash and cash equivalents (excluding subsequent $4.8 million raise)16,010 2,091,299 Total assets21,128,878 20,205,794 Total current liabilities2,155,424 4,455,764 Total liabilities15,133,893 15,985,466 Total shareholders’ equity5,994,985 4,220,328   The above selected financial data should be read in conjunction with the Company’s financial statements, the notes thereto and related management’s discussion and analysis for the three and nine months ended September 30, 2025 and 2024, copies of which are available under the Company’s profile at www.sedarplus.ca.

ABOUT SOUTH STAR BATTERY METALS CORP.

South Star is a Canadian battery-metals project developer focused on the selective acquisition and development of near-term production projects in the Americas. South Star’s Santa Cruz Graphite Project, located in Southern Bahia, Brazil is the first of a series of industrial- and battery-metals projects that South Star aims to put into production. Brazil is the second-largest graphite-producing region in the world with more than 80 years of continuous mining. Santa Cruz has at-surface mineralization in friable materials, and successful large-scale pilot-plant testing (> 30 tonnes) has been completed. The results of the testing show that approximately 65% of graphite concentrate is +80 mesh with good recoveries and 95%-99% graphitic carbon (Cg). With excellent infrastructure and logistics, South Star Phase 1 is ramping up commercial production with first sales shipped in May 2025. Santa Cruz is the first new graphite production in the Americas since 1996.

South Star’s second project in the development pipeline is strategically located in the center of a developing electric-vehicle, aerospace, and defense hub in Alabama, U.S.A. The BamaStar Project includes a historic mine active during the First and Second World Wars. The vertically integrated production facilities include a mine and industrial concentrator in Coosa County, AL and a downstream value-add plant in Mobile, AL, which will be upgrading natural flake graphite concentrates from both Santa Cruz and BamaStar mines. A NI 43-101 Preliminary Economic Assessment (the “PEA”) demonstrates strong economic results with a pre-tax Net Present Value (“NPV8%”) of US$2.4 billion and an Internal Rate of Return (“IRR”) of 35%, as well as an after-tax NPV8% US$1.6 billion with an IRR of 27% (for additional information on these figures and the underlying assumptions refer to the Company’s news release dated November 13, 2024 and the PEA, which are available under the Company’s profile at www.sedarplus.ca). South Star has also received US$3.2 million grant commitment from the US Department of Defense Title III program to advance a feasibility study on the BamaStar project. South Star trades on the TSX Venture Exchange under the symbol STS, and on the OTCQB under the symbol STSBF.

South Star is committed to a corporate culture, project execution plan and safe operations that embrace the highest standards of ESG principles, based on transparency, stakeholder engagement, ongoing education, and stewardship. To learn more, please visit the Company website at http://www.southstarbatterymetals.com.

The scientific and technical content of this news release was reviewed, verified, and approved by Marc Leduc, P. Eng., a “Qualified Person” under National Instrument 43-101 and Chairman of South Star Battery Metals Corp.

On behalf of the South Star Board of Directors,

MR. MARC LEDUC,
CHAIRMAN OF THE BOARD OF DIRECTORS

For additional information, please contact:

South Star Investor Relations

Email:[email protected]:+1 (604) 706-0212Website:www.southstarbatterymetals.comX:https://x.com/southstarbmFacebook:https://www.facebook.com/southstarbatterymetalsLinkedIn:https://www.linkedin.com/company/southstarbatterymetals/YouTube:https://www.youtube.com/@southstarbatterymetals6425  CAUTIONARY STATEMENT

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

FORWARD-LOOKING INFORMATION

This press release contains “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. Any statements that express predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”.

Forward-looking statements in this press release include, but are not limited to, realizing expected cost savings, obtaining critical equipment on expected timelines, achieving the design capacity of the Santa Cruz plant, the commencement and timing of production at the Santa Cruz Project; the scaling of operations and achieving breakeven operating levels and positive cash flow; entering into a loan facility with Sprott Streaming; and the Company’s overall strategy, plans, and future expectations.

Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation: risks related to failure to obtain adequate financing on a timely basis and on acceptable terms; risks related to the outcome of legal proceedings; political and regulatory risks associated with mining and exploration; risks related to the maintenance of stock exchange listings; risks related to environmental regulation and liability; the potential for delays in exploration or development activities or the completion of feasibility studies; the uncertainty of profitability; risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; results of prefeasibility and feasibility studies, and the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; risks related to commodity price fluctuations; and other risks and uncertainties related to the Company's prospects, properties and business detailed elsewhere in the Company's disclosure record. Additional information on these and other risk factors can be found in the Company’s continuous disclosure documents available under its profile on SEDAR+ at www.sedarplus.ca.

Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Investors are cautioned against attributing undue certainty to forward-looking statements. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances. Actual events or results could differ materially from the Company's expectations or projections.

Operating leverage continues to improve with gross margin outpacing revenue growth and operating expenses declining
November 27, 2025 6:30 PM EST | Source: NorthStar Gaming Holdings Inc.
Toronto, Ontario--(Newsfile Corp. - November 27, 2025) - NorthStar Gaming Holdings Inc. (TSXV: BET) (OTCQB: NSBBF) ("NorthStar" or the "Company") today announced its financial results for the three- and nine-month periods ended September 30, 2025. All dollar figures are quoted in Canadian dollars.

"We maintained our track record of year-over-year growth in both revenue and gross margin in the third quarter," said Michael Moskowitz, Chair and CEO of NorthStar. "We continue to strengthen the fundamentals of the business with KPIs remaining solid and ongoing innovation helping to attract and retain customers. Our team has been implementing operational improvements that are improving the player experience while at the same time reducing operating expenses."

Financial Highlights for the Third Quarter Ended September 30, 2025 ("Q3 2025"):

Revenue1 was $6.9 million in Q3 2025, a 4% increase from $6.6 million in Q3 2024. Revenue in Q3 2025 includes $0.8 million of managed services revenue, an increase of 167% from $0.3 million in Q3 2024, Revenues increased despite the higher than customary player-friendly outcomes of the quarter.Gross Margin was $2.4 million, a 14% increase from $2.1 million in Q3 2024, while the Gross Margin percentage increased to 34.7% of revenue, up from 31.7% in Q3 2024Profit before marketing and other expenses2 was $0.2 million in Q3 2025, an improvement of $0.7 million compared to a loss of $0.5 million in Q3 2024. This marks the fourth consecutive quarter of positive profit before marketing and other expenses.General and administrative ("G&A") expense was $2.2 million in Q3 2025, a decrease of 16% from $2.6 million in Q3 2024. G&A expense represented 31.6% of revenue compared to 39.4% in Q3 2024.Marketing expense was $2.3 million in Q3 2025, a decrease of 21% from $2.9 million in Q3 2024, and represented 32.6% of revenue compared to 42.9% in Q3 2024. The Company continues to optimize its marketing investments to reduce costs and attract high value players.Financial Highlights for the Nine-Month Period Ended September 30, 2025 ("YTD 2025"):

Revenue1 was $23.3 million in YTD 2025, a 17% increase from $20.0 million in YTD 2024. Revenue in YTD 2025 includes $1.9 million of managed services revenue, an increase of 138% from $0.8 million in YTD 2024.Gross Margin was $8.9 million, a 32% increase from $6.8 million in YTD 2024, while the Gross Margin percentage increased to 38.2% of revenue, up from 33.9% in YTD 2024.Profit before marketing and other expenses2 was $1.5 million in YTD 2025, an improvement of $2.2 million compared to a loss of $0.6 million in YTD 2024.G&A expense was $7.37 million in YTD 2025, a decrease of 1% from $7.42 million in YTD 2024, as savings realized throughout the G&A category were partially offset by $0.3 million of one-time expenses incurred in Q2 2025 associated with the restatement of prior financial results and disclosure review. As a percentage of revenue, G&A decreased to 31.6% in YTD 2025 compared to 37.1% a year earlier. Management has taken steps during the second half of 2025 to further reduce G&A through various initiatives, the full impact of which will likely be realized in 2026.Marketing expense of $9.4 million decreased 8% from $10.2 million in YTD 2024 and represented 40.4% of revenue compared to 51.0% in YTD 2024.Recent Operating Highlights:

Launched The Boost (www.theboostbet.ca), a website which showcases NorthStar's premium sports and casino content, including news, insights and scores, and targets a wider audience to help accelerate customer acquisition in Ontario.The Company's fall marketing campaign extended the "Exceptionally Canadian" theme - including television ads - to maximize awareness during the seasonally busy fourth quarter.NorthStar was recognized at the recent Clio Sports Awards, a program honouring excellence in advertising around the world. NorthStar won a Silver Award for its "SwiftBets" campaign which encouraged Taylor Swift fans to place prop bets on her Eras Tour performances in Toronto, and a Shortlist Award for its "Debatable Billboards" campaign on the soccer versus football debate.Built on our lead in online tournaments with a robust slate of fall events, including the return of the 50 Grand Slots Showdown and the NorthStar Blackjack Championship, along with the free-to-play NFL-themed Beat the Spread Challenge, the Sports Showdown Tournament, and a special Holiday Slots event. Continued to invest in our VIP infrastructure through new team members, events and incentives aimed at delivering a premium experience to the players who drive an outsized proportion of our results.Phase One of the new Casino lobby went live, delivering a smarter, faster experience that prioritizes top-performing titles and sets the foundation for a suite of personalization phases aimed at lifting play intensity, personalizing game rails to elevate discovery, and increase engagement.Implemented enhancements to our onboarding process which have led to 9% faster registration times, a 28% reduction in abandon rates, and an 8% uplift in the completion rate, illustrating the ongoing improvements to the customer journey that are critical to converting and retaining players.Outlook

"The third quarter of 2025 represented overall growth in NorthStar's revenue at a time where the Company's business is maturing and the Ontario iGaming market continues to evolve," said Mr. Moskowitz. "Looking ahead to 2026, the Company has adjusted its strategy to focus on a disciplined approach to optimize player acquisition and retention where these investments align with our financial resources and market conditions. As a result, management expects more moderate top-line growth driven by continued enhancements to the player experience and by prudent allocation of marketing and operating expenses."

The Company's unaudited condensed consolidated interim financial statements for the three- and nine-month periods ended September 30, 2025 ("Q3 2025 Financial Statements") includes a going concern statement. Continued revenue growth is dependent on the Company's ability to maintain adequate liquidity to support marketing and customer acquisition initiatives. Based on current forecasts, the Company's cash flow and liquidity position may not be sufficient to fund operating expenditures, including marketing investments, and meet certain debt-related covenants with its senior lender without further action.

Management has developed a cash flow forecast for the period to December 31, 2026 which indicates that the Company can continue to meet its obligations as they come due. However, there is a risk that the Company may breach certain debt-related covenants, and management has initiated discussions with the lender regarding these matters. A breach could require the Company to implement operational adjustments and, if necessary, seek additional debt or equity financing. Management continues to closely monitor the Company's liquidity position to ensure that operating cash flows remain sufficient to support ongoing obligations.

Additional details regarding the Company's financial outlook, liquidity and associated risks are described in the Company's management's discussion & analysis ("Q3 2025 MD&A").

Restatement of Results

The comparative results for the three- and nine-month periods ended September 30, 2024 have been restated in the Company's financial statements and the corresponding Q3 2025 MD&A to include additional merchant fees and player bonus expenses which were not captured in the previously published financial statements. Please refer to note 2 of the Company's Q3 2025 Financial Statements.

Additional Information

For additional information, please refer to the Q3 2025 Financial Statements and the corresponding Q3 2025 MD&A. These documents are available on SEDAR+ at www.sedarplus.ca, and on the Company's website at www.northstargaming.ca.

About NorthStar

NorthStar proudly owns and operates NorthStar Bets, a Canadian-born casino and sportsbook platform that delivers a premium, distinctly local gaming experience. Designed with high-stakes players in mind, NorthStar Bets Casino offers a curated selection of the most popular games, ensuring an elevated user experience. Our sportsbook stands out with its exclusive Sports Insights feature, seamlessly integrating betting guidance, stats, and scores, all tailored to meet the expectations of a premium audience.

As a Canadian company, NorthStar is uniquely positioned to cater to customers who seek a high-quality product and an exceptional level of personalized service, setting a new standard in the industry. NorthStar is committed to operating at the highest level of responsible gaming standards.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange ("TSXV") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Non-IFRS Financial Measures

Throughout this document, management uses certain non-IFRS financial measures and supplementary financial measures to evaluate the performance of the Company. The terms "Profit/(Loss) before marketing and other expenses" and "Loss before marketing expenses" are each a non-IFRS financial measure. These measures are not recognized measures under International Financial Reporting Standards ("IFRS") and do not have standardized meanings prescribed by IFRS and are, therefore, not necessarily comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management's perspective and to discuss NorthStar's financial outlook. Accordingly, these measures should not be considered in isolation nor as substitutes for analysis of the Company's financial information reported under IFRS. We believe that securities analysts, investors and other interested parties frequently use non-IFRS measures, including industry metrics, in the evaluation of companies in our industry. Management also uses non-IFRS measures and industry metrics in order to facilitate operating performance comparisons from period to period, the preparation of annual operating budgets and forecasts and to determine components of executive compensation.

Operating Results

Marketing expenses are a key driver of the business but are completely discretionary. Management considers "Profit/(Loss) before marketing and other expenses" and "Loss before other expenses" to be good indicators of the extent to which the business' Gross Margin is in excess of its overhead costs, and therefore offsetting some portion of marketing expenses, reflecting improving economies of scale.

$ Millions (unaudited)Three months endedNine months endedSept 30,
2025Sept 30,
2024Sept 30,
2025Sept 30,
2024Revenue$ 6,939$ 6,645$23,329$20,007Cost of Revenues4,5284,53814,41513,232Gross Margin2,4112,1078,9146,775General and administrative expenses2,1902,6177,3667,420Profit/(Loss) before marketing and 
other expenses (1)221(510)1,548(645)Marketing2,2592,8509,41410,207Loss before other expenses (1)(2,038)(3,360)(7,866)(10,852)Other expenses2,0522945,8674,713Net loss$(4,090)$(3,654)$(13,733)$(15,565)(1) These measures are not defined by IFRS, do not have standard meanings and may not be comparable with other industries or companies.

Cautionary Note Regarding Forward-Looking Information and Statements

This communication contains "forward-looking information" within the meaning of applicable securities laws in Canada ("forward-looking statements"), including without limitation, statements with respect to the following: expected performance of the Company's business, the Company's growth plans, the Company's strategies in connection with player acquisition, experience and retention, future growth opportunities for NorthStar, and the Company's liquidity plan and compliance with debt-related covenants. The foregoing is provided for the purpose of presenting information about management's current expectations and plans relating to the future and allowing investors and others to get a better understanding of the Company's anticipated financial position, results of operations, and operating environment. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates" or "believes", or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. This forward-looking information is based on management's opinions, estimates and assumptions that, while considered by NorthStar to be appropriate and reasonable as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking information. Such factors include, among others, the following: risks related to the Company's business and financial position; risks associated with general economic conditions; adverse industry risks; future legislative and regulatory developments; the ability of the Company to implement its business strategies; risks related to the Company's liquidity position; and those factors discussed in greater detail under the "Risk Factors" section of the Company's most recent annual information form and Q3 2025 MD&A, both of which are available under NorthStar's profile on SEDAR+ at www.sedarplus.ca. Many of these risks are beyond the Company's control.

If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking statements, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking statements. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this press release represents NorthStar's expectations as of the date specified herein, and are subject to change after such date. However, the Company disclaims any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276229

Calgary, Alberta / November 27, 2025 – TheNewswire - Credissential Inc. (“Credissential” or the “Company”) (CSE: WHIP) , a vertically integrated AI software development company , provides this biweekly status update in accordance with National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”).   As previously announced on October 29, 2025, the Company applied for and was granted a Management Cease Trade Order (“ MCTO ”) by the Alberta Securities Commission (“ ASC ”), as principal regulator, due to a delay in the filing of its audited annual financial statements, accompanying management's discussion and analysis, and the related CEO and CFO certifications for the fiscal year ended June 30, 2025 (collectively, the “ Annual Filings ”).

November 27, 2025 19:02 ET

 | Source:

Optiva Inc.

TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Optiva Inc. (TSX: OPT) ("Optiva") is pleased to announce that the shareholders of Optiva (the "Shareholders") and the holders (the "Noteholders") of principal amount of 9.75% senior secured payment-in-kind toggle notes ("PIK Notes") have approved the proposed plan of arrangement (the "Arrangement") involving Qvantel Oy (the "Purchaser") at the special meeting of Shareholders (the "Shareholder Meeting") and special meeting of Noteholders (the "Noteholder Meeting" and collectively with the Shareholder Meeting, the "Meetings") held earlier today.

Pursuant to the Arrangement, (i) the Purchaser will acquire all of the issued and outstanding common shares of Optiva (the "Shares") for a price of C$0.25 per Share, and (ii) the PIK Notes will be cancelled and the Noteholders will ultimately (following all intermediate steps in the Arrangement) be entitled to receive (i) voting shares of the Purchaser (the "Purchaser Shares") representing in aggregate approximately 22.4% of the Purchaser Shares on a non-diluted basis, (ii) secured notes issued by the Purchaser in the aggregate principal amount of US$25 million, subject to adjustment in certain circumstances in accordance with the terms of the Arrangement, (iii) warrants to purchase such number of additional Purchaser Shares as is equal to 3% of the outstanding Purchaser Shares on a non-diluted basis, (iv) a cash payment at closing (if any), to the extent Optiva has a cash surplus at closing above a specified cash target, and (v) a deferred cash payment (if any) payable post-closing up to a maximum aggregate amount of US$700,000, to the extent there are surplus accounts receivables above a specified target and such accounts are collected within a specified period post-closing, which in each case shall be allocated on a pro rata basis among the Noteholders based on the aggregate principal amount of PIK Notes held by such Noteholder prior to the effective time of the Arrangement.

To be effective, the special resolution approving the Arrangement (the "Arrangement Resolution") required (i) the affirmative vote of at least two-thirds of the votes cast by Shareholders present or represented by proxy at the Shareholder Meeting, (ii) a simple majority of the votes cast by Shareholders present in person or represented by proxy at the Shareholder Meeting, other than the votes cast by EdgePoint Investment Group Inc. and Mr. Robert Stabile, which were excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Shareholders in Special Transactions ("Minority Shareholders"), and (iii) votes cast by at least two-thirds (66 ⅔%) of the aggregate principal amount of PIK Notes present in person or represented by proxy at the Noteholder Meeting.

At the Meetings, the Arrangement Resolution was approved by: (i) 96.10% of the votes cast by Shareholders, (ii) 93.34% of the votes cast by Minority Shareholders, and (iii) 100% of the votes cast by Noteholders, in each case, present or represented by proxy at the Meetings. Accordingly, all requisite Shareholder and Noteholder approvals required in order to proceed with the Arrangement have been obtained. Additional details of the voting results will be included in a report of voting results to be filed on SEDAR+ (www.sedarplus.ca) under Optiva's issuer profile.

The Arrangement is expected to become effective before the end of the year, subject to, among other things, Optiva obtaining a final order from the Ontario Superior Court of Justice (Commercial List) approving the Arrangement (the "Final Order") and the satisfaction or waiver of certain other customary closing conditions. The Final Order hearing is scheduled to take place on December 2, 2025.

It is expected that, within two to three business days following the completion of the Arrangement, the Shares will be delisted from the Toronto Stock Exchange. Additional details about the Arrangement and the Arrangement Resolution can be found in the management information circular of Optiva dated October 27, 2025, a copy of which is available on SEDAR+ (www.sedarplus.ca) under Optiva's issuer profile.

About Optiva Inc:

Optiva Inc. is a leading provider of mission-critical, cloud-native, agentic AI-powered revenue management software for the telecommunications industry. Its products are delivered globally on the private and public cloud. Optiva's solutions help service providers maximize digital, 5G, IoT and emerging market opportunities to achieve business success. Established in 1999, Optiva Inc. is listed on the Toronto Stock Exchange (TSX:OPT). For more information, visit www.optiva.com.

For additional information, please contact:

Optiva Media and Analyst Relations

Misann Ellmaker

[email protected]

Optiva Investor Relations

[email protected]

Cautionary Note – Forward Looking Statements

Certain statements contained in this news release contain "forward-looking information" within the meaning of applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might", "have potential" or "will" be taken, occur or be achieved) are not statements of historical fact and may be "forward-looking statements." Forward-looking information and statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to a variety of risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Forward-looking information and statements include, but are not limited to, statements regarding the timing and ability of Optiva to implement the Arrangement (if at all); the timing and ability of Optiva to obtain the final order (if at all); the timing and ability of Optiva and the Purchaser to satisfy the conditions precedent to the completion of the Arrangement (if at all); and the timing to delist the Shares of Optiva (if at all).

Although Optiva believes that the expectations reflected in such forward-looking information and statements are reasonable, such information and statements involve risks and uncertainties, and undue reliance should not be placed on such information and statements. Material factors or assumptions that were applied in formulating the forward-looking information contained herein include, without limitation, the expectations and beliefs of Optiva, and its management and board of directors, as of the date hereof. Optiva cautions that the foregoing list of material factors and assumptions is not exhaustive. Many of these assumptions are based on factors and events that are not within its control, and there is no assurance that they will prove correct. Consequently, there can be no assurance that the actual results or developments anticipated by Optiva will be realized or, even if substantially realized, that they will have the expected consequences for, or effects on, Optiva, the current Shareholders, or its future results and performance of Optiva. For additional information with respect to these and other factors and assumptions underlying the forward-looking statements made in this news release concerning the Arrangement, see the management information circular of Optiva dated October 27, 2025 available on SEDAR+ (www.sedarplus.ca) under Optiva's issuer profile.

Readers, therefore, should not place undue reliance on any such forward-looking statements. There can be no assurance that the Arrangement will be completed or that it will be completed on the terms and conditions contemplated in this news release. The Arrangement could be modified or terminated in accordance with its terms. Further, the forward-looking information and statements in this news release are based on beliefs and opinions of Optiva at the time the statements are made, and there should be no expectation that these forward-looking statements will be updated or supplemented as a result of new information, estimates or opinions, future events or results or otherwise, and Optiva disavows and disclaims any obligation to do so except as required by applicable law. Nothing contained herein shall be deemed to be a forecast, projection or estimate of the future financial performance of Optiva.

Oceana Group Limited (OTCPK:OCGPF) Q4 2025 Earnings Call November 23, 2025 7:00 PM EST

Company Participants

Neville Brink - CEO & Executive Director
Zafar Mahomed - CFO & Executive Director

Presentation

Neville Brink
CEO & Executive Director

Good morning, everybody, and thank you for joining us on this fine Monday morning in Cape Town, our annual results presentation for 2025. And let me just take you through the format. So we've got about 1.5 hours. I will take you through an overview and I'll cover our three pillars, and then I'll hand over to Zaf, who will take us through the financial results, and then I'll go back to our outlook and give you an indication of what we're facing for the next year and then happy to answer some questions. So let's kick off.

Just when -- and I just want to take you back a step, what I've done is slightly different this presentation. I put four context slides in the presentation, one for group and one for each of the divisions. And the purpose of that is to give you a view not only of the numbers of the environment that it currently exists both from a group point of view and each of the divisions and what they're facing and some of the issues that affect their business.

And I want to start off with the group because we put out a trading statement about 2 months ago. And obviously, you've all seen the trading statement and it showed our figures, our results were going to be somewhere between 38% and 42% down. And immediately, I started getting questions from the market and from friends and everybody about Oceana. Was Oceana in trouble, what was happening. And it made me think a bit about where Oceania is quite right now. And the more I thought about it, the more

Recommended For You

November 27, 2025 7:20 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 27, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline.

SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to the G6 and G7 continuous glucose monitoring ("CGM") systems that were unauthorized by the U.S. Food and Drug Administration (the "FDA"); (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (4) Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (6) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276107

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease

November 27, 2025 19:30 ET

 | Source:

Biogen Inc.

TOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for “LEQEMBI®” (brand name, generic name: lecanemab) seeking approval for a subcutaneous formulation (subcutaneous autoinjector: SC-AI) as a new route of administration to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

The application is based on data from multiple subcutaneous (SC) administration sub-studies of lecanemab conducted as part of the Phase 3 Clarity AD open-label extension (OLE), following the 18-month core study in individuals with Mild Cognitive Impairment (MCI) due to Alzheimer‘s disease (AD) or mild stage of AD dementia (collectively referred to as early AD). It was confirmed that the once-weekly administration of SC-AI 500mg resulted in equivalent exposure to once every two weeks intravenous (IV) administration and similar clinical and biomarker benefits. Subcutaneous administration demonstrated a safety profile similar to IV administration, with less than 2% incidence of systemic injection/infusion-related reactions.

If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration every two weeks dose in the hospital setting. The potential approval of SC-AI would expand the option for patients and care partners to receive LEQEMBI treatment at home. The injection time for each autoinjector (250mg injection) is approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion and nurse monitoring, while streamlining the overall AD treatment care pathway.

AD is a progressive, relentless disease with amyloid beta (Aβ) and tau as hallmarks that is caused by a continuous underlying neurotoxic process driven by protofibrils* that begins before amyloid plaque accumulation and continues after plaque removal.1,2,3 Only LEQEMBI fights AD in two ways – targeting both protofibrils and amyloid plaque, which can impact tau downstream.

LEQEMBI is currently approved in 51 countries and regions and is under regulatory review in 9 countries.

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2

MEDIA CONTACTS Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120Eisai Europe, Ltd.
EMEA Communications Department
+44 (0) 797 487 9419
[email protected]

Eisai Inc. (U.S.)
Libby Holman
+1-201-753-1945
[email protected]

Biogen Inc.
Madeleine Shin 
+1-781-464-3260
[email protected] INVESTOR CONTACTS Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122Biogen Inc.
Tim Power
+ 1-781-464-2442
[email protected]
Notes to Editors

About lecanemab (generic name, brand name: LEQEMBI®)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has been approved in 51 countries and regions including Japan, the United States, Europe, China, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 9 countries. Leqembi received manufacturing and marketing approval in Japan on September, 2023 for the indication of a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in the U.S., China, he United Kingdom, and others, and applications have been filed in 4 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A rolling Supplemental Biologics License Application (sBLA) for initiation treatment was initiated under Fast Track status in September 2025, and completed in November 2025.

Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd. 
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for LEQEMBI (lecanemab) subcutaneous autoinjector (SC-AI); the potential to streamline the Alzheimer's disease treatment pathway; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References

Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Hampel H, Hardy J, Blennow K, et al. The amyloid pathway in Alzheimer's disease.
Mol Psychiatry. 2021;26(10):5481-5503.

Q4: 2025-11-25 Earnings SummaryEPS of -$0.18 misses by $0.02

 |

Revenue of

$256.47M

beats by $99.17M

Arrowhead Pharmaceuticals, Inc. (ARWR) TD Cowen Treatment Advancements in Obesity and Related Disorders Summit November 24, 2025 1:30 PM EST

Company Participants

James Hamilton - Chief Medical Officer and Head of R&D

Conference Call Participants

Joseph Thome - TD Cowen, Research Division

Presentation

Joseph Thome
TD Cowen, Research Division

Everyone, and thank you for joining us at TD Cowen's 2025 Treatment Advances in Obesity Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen. And it is my pleasure to have with me today Dr. James Hamilton, who is the Chief Medical Officer and Head of Research and Development of Arrowhead Pharmaceuticals. So thanks for joining us.

Maybe before we get into some of the specific programs, it might be helpful just to level set and kick off the discussion with just a brief overview of Arrowhead's recent progress and accomplishments. Obviously, we saw the update on the Sarepta partnership this morning, which is great to see. And then maybe what should investors be expecting into the end of the year and into 2026? And then we can kind of go from there.

James Hamilton
Chief Medical Officer and Head of R&D

Yes, sure. Happy to cover all of that, and thanks for having me. Thanks for the invitation to present today. In terms of what we have going forward end of this year, into next year, of course, I'm sure everybody saw the recent first approval of REDEMPLO in FCS. And we've got -- our quarterly call is tomorrow, so we'll give some updates on launch progress around REDEMPLO.

Then in addition to that, specific to the obesity space, we do still plan to provide an update and release some data from our INHBE and ALK7 programs over that time frame. Probably like first

Recommended For You

November 27, 2025 8:04 PM EST | Source: Atomic Minerals Corp.
Vancouver, British Columbia--(Newsfile Corp. - November 27, 2025) - Atomic Minerals Corporation (TSXV: ATOM) (FSE: DO80) (OTCID: ATMMF) ("Atomic Minerals" or the "Company") is pleased to announce that, due to strong investor demand, it has increased the size of its previously announced non-brokered private placement pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions (the "Listed Issuer Financing Exemption") to up to 14,666,667 units ("Units") (previously 12,000,000 Units) at a price of $0.05 per Unit, for gross proceeds of up to $733,333 (previously $600,000) (the "Life Offering"). The Company also announces that it has increased the size of its concurrent non-brokered private placement to up to 29,333,333 Units (previously 24,000,000 Units) at a price of $0.05 per Unit, for gross proceeds of up to $1,466,666 (previously $1,200,000) (the "Concurrent Private Placement").

Each Unit will consist of one common share in the capital of the Company (a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder to acquire one Share at a price of $0.10 per Share for a period of 12 months from the date of issuance, provided that the Warrants issued under the LIFE Offering will not be exercisable for a period of 60 days after the date of issue.

The LIFE Offering is available to purchasers' resident in Canada, except Québec, pursuant to the Listed Issuer Financing Exemption. The Concurrent Private Placement is available to purchasers' resident in Canada pursuant to other prospectus exemptions of NI 45-106. The securities offered under the LIFE Offering will not be subject to a hold period in accordance with applicable Canadian securities laws. The securities offered under the Concurrent Private Placement will be subject to a statutory hold period in Canada ending on the date that is four months plus one day following the closing date of the Concurrent Private Placement.

There is an amended and restated offering document related to the LIFE Offering that can be accessed under the Company's profile on SEDAR+ at www.sedarplus.ca and on the Company's website at: www.atomicminerals.ca. Prospective investors should read this offering document before making an investment decision.

The Company expects to pay finders' fees to eligible parties in accordance with applicable securities laws and the policies of the TSX Venture Exchange (the "TSXV"). The finders' fees will consist of cash of between 5%-8% of the proceeds raised under the LIFE Offering and the Concurrent Private Placement and finder warrants equal to up to 8% of the Units sold under the LIFE Offering and Concurrent Private Placement. Each finder warrant will be exercisable to acquire one Share at a price of $0.10 for a period of one year.

The LIFE Offering and the Concurrent Private Placement is expected to close on December 1, 2025 and is subject to customary regulatory approvals, including approval of the TSXV. The Company intends to use the net proceeds of the LIFE Offering and the Concurrent Private Placement to fund exploration activities at its uranium projects located in Saskatchewan and the Colorado Plateau region of the United States and for general administrative expenses.

The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered or exempt from registration. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States.

About Atomic Minerals Corporation.

Atomic Minerals Corporation is a publicly listed exploration company on the TSXV, trading under the symbol ATOM, led by a highly skilled management and technical team with a proven track record in the junior mining sector. Atomic Minerals' objective is to identify exploration opportunities in regions that have been previously overlooked but are geologically similar to those with previous uranium discoveries. These underexplored areas hold immense potential and are in stable geopolitical and economic environments.

Atomic Minerals' property portfolio contains uranium projects in three locations within North America, all of which have significant technical merit and or are known for hosting uranium production in the past. Four of the properties are located on the Colorado Plateau, an area which has previously produced 597 million pounds of U3O8; the Mozzie Lake project is located in the prolific Athabasca Basin region in Northern Saskatchewan and the Mont-Laurier project is located in Quebec.

For additional information about the Company and its projects, please visit our website at www.atomicminerals.ca

ON BEHALF OF THE BOARD OF DIRECTORS

"Clive H. Massey"
Clive H. Massey
President & Chief Executive Officer

Cautionary Statement on Forward Looking Information

Certain statements made and information contained herein may constitute "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation. These statements and information are based on facts currently available to the Company and there is no assurance that actual results will meet management's expectations. Forward-looking statements and information may be identified by such terms as "anticipates", "believes", "targets", "estimates", "plans", "expects", "may", "will", "speculates", "could" or "would". These forward-looking statements or information relate to, among other things: the completion of the Life Offering and the Concurrent Private Placement; the anticipated closing date; the anticipated proceeds to be raised under the LIFE Offering and the Concurrent Private Placement; the intended use of proceeds from the Life Offering and the Concurrent Private Placement; and the receipt of all necessary approvals for the completion of the Life Offering and the Concurrent Private Placement, including the approval of the TSXV.

Such forward-looking information and statements are based on numerous assumptions, including among others, that the Company will complete the Life Offering and the Concurrent Private Placement on the terms as anticipated by management, that the Company will be able to raise the anticipated proceeds under the LIFE Offering and the Concurrent Private Placement; that the closing will occur on the date disclosed; and that the Company will receive all necessary approvals for the completion of the Life Offering and the Concurrent Private Placement, including the approval of the TSXV. Although the assumptions made by the Company in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

All of the forward-looking statements made in this document are qualified by these cautionary statements. Important factors that could cause actual results to differ materially from the Company's plans or expectations include risks relating to the failure to complete the LIFE Offering and the Concurrent Private Placement in the timeframe and on the terms as anticipated by management, that the closing of the LIFE Offering and the Concurrent Private Placement will be delayed, the inability of the Company to raise the anticipated proceeds under the LIFE Offering and the Concurrent Private Placement, market conditions, metal prices, and risks relating to the Company not receiving all necessary approvals for the completion of the Life Offering and the Concurrent Private Placement, including the approval of the TSXV. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, forecast or intended and readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking information. Accordingly, there can be no assurance that forward-looking information will prove to be accurate and forward-looking information is not a guarantee of future performance. Readers are advised not to place undue reliance on forward-looking information. The forward-looking information contained herein speaks only as of the date of this document. The Company disclaims any intention or obligation to update or revise forward-looking information or to explain any material difference between such and subsequent actual events, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Not for Distribution to US Newswire Services or Dissemination in the United States of America

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276239